Detalhe da pesquisa
1.
Early dose reduction/delay and the efficacy of liposomal irinotecan with fluorouracil and leucovorin in metastatic pancreatic ductal adenocarcinoma (mPDAC): A post hoc analysis of NAPOLI-1.
Pancreatology
; 21(1): 192-199, 2021 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-33214082
2.
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Lancet
; 387(10018): 545-557, 2016 Feb 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-26615328
3.
First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: A phase I/II study.
Eur J Cancer
; 151: 14-24, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33957442
4.
Population pharmacokinetics of liposomal irinotecan in patients with cancer and exposure-safety analyses in patients with metastatic pancreatic cancer.
CPT Pharmacometrics Syst Pharmacol
; 10(12): 1550-1563, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34750990
5.
Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA).
J Clin Oncol
; 39(10): 1108-1118, 2021 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33555926
6.
Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial.
Clin Cancer Res
; 27(18): 5020-5027, 2021 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34253578
7.
Survival with nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in per-protocol and non-per-protocol populations of NAPOLI-1: Expanded analysis of a global phase 3 trial.
Eur J Cancer
; 105: 71-78, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30414528